<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01385800</url>
  </required_header>
  <id_info>
    <org_study_id>TG002</org_study_id>
    <nct_id>NCT01385800</nct_id>
  </id_info>
  <brief_title>ToleroMune Grass Exposure Unit Study</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled Study to Evaluate Three Doses of ToleroMune Grass in Grass Allergic Subjects Following Challenge With Grass Allergen in an Environmental Exposure Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adiga Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharm-Olam International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Grass pollen allergens are recognised as a major cause of allergic diseases in humans and
      animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen
      allergens and between 50-90% of hayfever or seasonal allergy sufferers are allergic to grass
      pollen. ToleroMune Grass is a novel, synthetic, allergen-derived peptide desensitising
      vaccine, currently being developed for the treatment of grass allergy.

      This study will look at the efficacy, safety and tolerability of three doses of ToleroMune
      Grass in grass allergic subjects following challenge with with grass in an Environmental
      Exposure Unit (EEU).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a randomised, double-blind, placebo-controlled, parallel group
      study to evaluate the safety and tolerability of ToleroMune Grass in grass allergic subjects
      with allergic rhinoconjunctivitis. The efficacy of ToleroMune Grass will be explored in
      subjects using an EEU (Environmental Exposure Unit).

      The study will consist of 3 study periods. In Period 1, Screening will be performed up to a
      maximum of 16 weeks before randomisation and may consist of one or two visits to the clinic,
      at the Investigator's discretion. Baseline Challenge will consist of 4 visits to the EEU at
      least 3 days before randomisation.

      In Period 2, subjects in each cohort complying with the inclusion/exclusion criteria will be
      randomised to one of four groups and will receive treatment every 2 weeks (Â±2 days) for 14
      weeks.

      In Period 3, Post Treatment Challenge will consist of 4 visits to the EEU about 25 weeks
      after the first administration in the treatment period and assessments will be performed
      identical to those at the baseline challenge. Follow-up will be conducted 3-10 days after
      PTC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Rhinoconjunctivitis Symptom Score</measure>
    <time_frame>Upto 25 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom scores for nasal and non nasal symptoms</measure>
    <time_frame>Upto 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin prick testing</measure>
    <time_frame>Upto 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Nasal Inspiratory Flow</measure>
    <time_frame>Up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grass specific IgA</measure>
    <time_frame>Upto 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grass specific IgE</measure>
    <time_frame>Upto 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grass specific IgG4</measure>
    <time_frame>Up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up tp 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Grass Allergy</condition>
  <condition>Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intradermal injection, 1 x 8 administrations 2 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ToleroMune Grass Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal injection 1 x 8 administrations 2 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ToleroMune Grass Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal injection 1 x 8 administrations 2 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ToleroMune Grass Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal injection 1 x 8 administrations 2 weeks apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ToleroMune Grass</intervention_name>
    <description>Intradermal injection 1 x 8 administrations 2 weeks apart</description>
    <arm_group_label>ToleroMune Grass Dose 1</arm_group_label>
    <arm_group_label>ToleroMune Grass Dose 2</arm_group_label>
    <arm_group_label>ToleroMune Grass Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intradermal injection 1 x 8 administrations 2 weeks apart</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Male or female, aged 18-65 years.

          -  Minimum 2-year documented history of rhinoconjunctivitis on exposure to grass.

          -  Positive skin prick test to grass allergen.

          -  Minimum qualifying rhinoconjunctivitis symptom scores

        Exclusion criteria

          -  History of asthma.

          -  A history of anaphylaxis to grassallergen.

          -  Subjects with an FEV1 &lt;80% of predicted.

          -  Subjects who cannot tolerate baseline challenge in the EEU.

          -  Subjects for whom administration of epinephrine is contra-indicated (e.g. subjects
             with acute or chronic symptomatic coronary heart disease or severe hypertension).

          -  A history of severe drug allergy, severe angioedema or anaphylactic reaction to food.

          -  A history of any significant disease or disorder (e.g. cardiovascular, pulmonary,
             gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic,
             neoplastic/malignant, psychiatric, major physical impairment).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne K Ellis, MD MSC FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University, Kingston, Ontario</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2011</study_first_submitted>
  <study_first_submitted_qc>June 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2011</study_first_posted>
  <last_update_submitted>August 14, 2013</last_update_submitted>
  <last_update_submitted_qc>August 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Grass allergy</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <keyword>Environmental Exposure Unit</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>ToleroMune Grass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

